Feature | July 25, 2013

First Robotic-Assisted STEMI Stent Performed at Sanford Aberdeen Medical Center

Interventional cardiologist performs CorPath Robotic angioplasty, door-to-balloon time superior to national average

CorPath Robotic Angioplasty Corindus Sanford Aberdeen Medical Center South Dakot

July 25, 2013 — Sanford Aberdeen Medical Center in Aberdeen, S.D. became the first hospital to perform a robotic angioplasty for a patient with an acute heart attack, achieving a far better door-to-balloon time than the national standard. Interventional cardiologist Puneet Sharma, performed the percutaneous coronary intervention (PCI) to treat a patient that had experienced a heart attack and presented to the Sanford Aberdeen emergency department. Utilizing the U.S. Food and Drug Administration (FDA)-cleared CorPath System, Sharma was able to perform the robotic-assisted angioplasty procedure and restore blood flow to the patient’s heart within 68 minutes of their arrival.

The current nationwide standard for door-to-balloon time — from when a patient with a heart attack is presented to the emergency department (ED) to inflating a balloon in his coronary arteries to restore blood flow to the heart — is 90 minutes. These standards were developed by the American College of Cardiology (ACC) to improve timely access to the cath lab and by that improving clinical outcome.

“Timely access to emergency cardiac care and survival is partly dependent on access to services and technology,” said Sharma. “Being able to perform a CorPath Robotic Angioplasty on a STEMI patient within 68 minutes is a great benefit. As shown with the latest procedure, robotic-assisted angioplasties improve rural access and quality of care as more patients in this area will have access for advanced specialty care. The implementation of the CorPath System and its ability to precisely and rapidly execute an angioplasty procedure with only one stent in the patient heart is a great example of Sanford Health’s commitment to enhanced clinical outcome for our patients.”

The CorPath System is the first and only FDA cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Seated in an interventional cockpit, the interventional cardiologist advances stents and guidewires via a joystick with millimeter-by-millimeter precision. The system, which is quickly being adopted as the new standard of care in coronary angioplasty procedures, may also improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

Sanford Health performs robotic-assisted angioplasty procedures with the CorPath System at both Sanford Heart Hospital in Sioux Falls and Sanford Aberdeen Medical Center. It is the first and only health system in the region utilizing the CorPath System.

For more information: www.corindus.com

Related Content

Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Overlay Init